

Call for Proposals



ADVANCE

Global Awards for Advancing
Chronic Pain Research

Funding innovative, novel research proposals that seek to advance the understanding and management of chronic pain

Pfizer Inc. and Eli Lilly and Company are pleased to announce the call for proposals for the 3rd Global Awards for Advancing Chronic Pain Research (ADVANCE) in 2020.

ADVANCE is a competitive awards program and will provide a unique opportunity for Pfizer Inc. and Eli Lilly and Company to support chronic pain research at medical and research institutions throughout the world.

Proposals will be reviewed by an external multidisciplinary, Independent Review Committee comprising renowned, global experts in chronic pain. The assessment process is completely independent of Pfizer Inc. and Eli Lilly and Company, with final responsibility for selection of Awardees resting with the Co-Chairs.

The intent of the program is to fund approximately 5 grants between US \$50,000 and US \$200,000, from a total fund of US \$1 million.

Areas of research that are considered **in-scope** for an ADVANCE research grant, with the condition of interest being osteoarthritis (OA) and chronic pain associated with OA, will include studies that aim to advance the understanding of the following:

- Evaluation of unmet medical needs in pain management associated with OA, as follows:
 - Benefit-risk assessment and patient preference in the choice of pain medication for patients with comorbid conditions (e.g., cardiovascular disease or history of substance abuse)
 - How risks associated with long-term use of analgesics are assessed currently
 - Treatment of chronic pain in special populations (e.g., postsurgical, elderly)
- Evaluation of multidisciplinary approaches to management of OA (e.g., physical therapy, cognitive behavioral therapy) and their combination with pharmacological treatment
- Understand and predict response to treatment, disease state, and course of OA (normal and rapid trajectories)
- Approaches to improving adherence to therapy or therapeutic regimens for pain associated with OA
- Use of patient characteristics such as biomarkers or other objective evaluations (e.g., quantitative sensory testing, imaging modalities) in the assessment and management of OA to better understand disease course
- Evaluation of improved function
 - How changes of physical function are assessed in clinical practice in patients with OA, and how current physical function assessment could be improved
 - How individual goal setting can contribute to treatment outcome (including pain and function)
 - What impact the improved physical function has on the patient's quality of life

Areas that are considered **out of scope** and will NOT be considered for an ADVANCE research grant include:

- Studies not involving OA
- Preclinical research
- Studies involving pregnant or lactating females and/or participants <18 years of age
- Drug requests
- Requests for funding from countries that currently have restrictions on trade with the United States

For further information about ADVANCE, including how to apply, please visit www.advanceresearchawards-chronicpain.com

**Application Deadline:
September 15, 2020**

